Pfizer's Atirmociclib Delivers Positive Phase 2 Results in Metastatic Breast Cancer on March 17, 2026 Atirmociclib Carcinoma breast stage IV CDK4 inhibitor Pfizer Phase 2 second-line treatment +
Eli Lilly’s Jaypirca pushes into first-line CLL, but commercial upside may be limited on December 10, 2025 Bruin-CLL-314 Chronic Lymphocytic Leukemia CLL eli lilly First line treatment Imbruvica Jaypirca Pirtobrutinib second-line treatment SLL +
FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma on July 21, 2025 Columvi Complete Diffuse Large B-Cell Lymphoma genentech rejection Response Letter Roche (company) second-line treatment STARGLO United States Food and Drug Administration +